

Halaven

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:		Date :
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
Referring Provider Info: 🗖 Same as Re	equesting Prov	vider
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: Same as Re		
Name: Fax:		NPI#:Phone:
Required Demographic Information: Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	e reauested dru	g·
\square Ambulatory Surgical		
☐ On Campus Outpatient Hospital		
	_ 0,,,,,,,	
Drug Information:		
Strength/Measure		Units □ ml □ Gm □ mg □ ea □ Un
Directions(sig)		Route of administration
Dosing frequency		

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Halaven SGM 1893-A – 08/2022.

<u>Cri</u>	iteria Questions: What is the patient's diagnosis?
1.	□ Breast cancer
	☐ Liposarcoma
	☐ Angiosarcoma
	☐ Pleomorphic rhabdomyosarcoma
	☐ Retroperitoneal/intra-abdominal soft tissue sarcoma
	☐ Extremities/body wall or head/neck soft tissue sarcoma
	□ Solitary fibrous tumor
	□ Other
2.	What is the ICD-10 code?
3.	Is this a request for continuation of therapy with the requested drug? \square Yes \square No If No, skip to diagnosis section.
4.	Has the patient experienced disease progression or unacceptable toxicity with the requested drug? ☐ Yes ☐ No No further questions
Co	mplete the following section based on the patient's diagnosis, if applicable.
Sec	ction A: Breast Cancer
5.	Does the patient have recurrent or metastatic disease?
	Recurrent disease
	☐ Metastatic disease ☐ None of the above
	None of the above
6.	What is the patient's human epidermal growth factor receptor 2 (HER2) status?
	ACTION REQUIRED: Attach human epidermal growth factor receptor 2 (HER2) testing results.
	☐ HER2-positive
	☐ HER2-negative, skip to #8
	☐ Unknown
7.	Will the requested drug be given in combination with trastuzumab or margetuximab?
	questions
8.	Will the requested drug be given as a single agent? ☐ Yes ☐ No
Sec	ction B: Liposarcoma, Angiosarcoma, Pleomorphic Rhabdomyosarcoma, Retroperitoneal/Intra-Abdominal Soft
	sue Sarcoma, Extremities/Body Wall or Head/Neck Soft Tissue Sarcoma, or Solitary Fibrous Tumor
9.	Will the requested drug be given as single-agent therapy? ☐ Yes ☐ No
I as	ttest that this information is accurate and true, and that documentation supporting this
	ormation is available for review if requested by Priority Partners.
,	2
X _	
Pre	escriber or Authorized Signature Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Halaven SGM 1893-A - 08/2022.